InnoCare Pharma receives approval from the NMPA to conduct Phase II/III clinical trial of TYK2 inhibitor soficitinib for chronic spontaneous urticaria (CSU), a condition affecting millions worldwide. Soficitinib targets key signaling pathways to reduce itch and inflammation in CSU patients, offering hope for improved disease management. With an estimated global CSU treatment market of $3 billion in 2029, InnoCare aims to address unmet medical needs through innovative drug development. CEO Dr. Jasmine Cui emphasizes the company’s commitment to advancing treatments for autoimmune diseases, positioning InnoCare as a leader in the field of dermatology.

Read more at GlobeNewswire: InnoCare Announces Approval of Phase II/III Clinical Trial